相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Soo Lim et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2021)
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Sabine Kahl et al.
DIABETES CARE (2020)
The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD
Maya Balakrishnan et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2020)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Propensity score methods in real-world epidemiology: A practical guide for first-time users
Yoon Kong Loke et al.
DIABETES OBESITY & METABOLISM (2020)
Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus
Naoyuki Fujimori et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2020)
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
Masanori Shimizu et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
Yoshio Sumida et al.
HEPATOLOGY RESEARCH (2019)
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Aino Latva-Rasku et al.
DIABETES CARE (2019)
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2019)
Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus
Norio Akuta et al.
HEPATOLOGY RESEARCH (2019)
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
Soo Lim et al.
OBESITY REVIEWS (2019)
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
Mitsuko Inoue et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Yong-ho Lee et al.
DIABETES & METABOLISM JOURNAL (2019)
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
David E. Kleiner et al.
JAMA NETWORK OPEN (2019)
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Mee Kyoung Kim et al.
DIABETES & METABOLISM JOURNAL (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
Soo Lim et al.
ATHEROSCLEROSIS (2018)
Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis
Veeral Ajmera et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
Noboru Kurinami et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Jan W. Eriksson et al.
DIABETOLOGIA (2018)
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
Seigo Sugiyama et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2018)
Noninvasive biomarkers in NAFLD and NASH - current progress and future promise
Vincent Wai-Sun Wong et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
F. Bonnet et al.
DIABETES & METABOLISM (2018)
Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
Dug-Hyun Choi et al.
ENDOCRINOLOGY AND METABOLISM (2018)
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study
Takashi Shibuya et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
Yuya Seko et al.
HEPATOLOGY RESEARCH (2017)
The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
Akihiko Takeda et al.
INTERNAL MEDICINE (2017)
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis A Meta-analysis
Giovanni Musso et al.
JAMA INTERNAL MEDICINE (2017)
Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes
Li Tang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Jeffrey Cui et al.
JOURNAL OF HEPATOLOGY (2016)
Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials
Lingling He et al.
MEDICINE (2016)
Non-alcoholic fatty liver disease and diabetes
Jonathan M. Hazlehurst et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders
Soo Lim et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Radiologic evaluation of nonalcoholic fatty liver disease
Seung Soo Lee et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis
J. H. Hoofnagle et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)
Siddharth Verma et al.
LIVER INTERNATIONAL (2013)
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Seoul National University Bundang Hospital's Electronic System for Total Care
Sooyoung Yoo et al.
HEALTHCARE INFORMATICS RESEARCH (2012)
Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
Jeong-Hoon Lee et al.
DIGESTIVE AND LIVER DISEASE (2010)
The utility of radiological imaging in nonalcoholic fatty liver disease
S Saadeh et al.
GASTROENTEROLOGY (2002)
分享论文
